Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.56
-0.14 (-1.31%)
Oct 6, 2026, 1:21 PM EDT - Market open
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$2,230,672
Profits / Employee
$938,475
Market Cap
627.09M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 2 | 3.39% | 61 | 0 |
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| CorMedix | 191 |
| DBV Technologies | 170 |
| MapLight Therapeutics | 133 |
| Aura Biosciences | 113 |
| Silence Therapeutics | 88 |
| Crescent Biopharma | 69 |
| CytomX Therapeutics | 69 |
ZVRA News
- 21 days ago - Zevra Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 21 days ago - Zevra Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 22 days ago - Zevra Therapeutics Slides: Corporate presentation - Filings
- 27 days ago - Zevra Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Zevra Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 month ago - Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts